After completing the independent medical educational activity, learners will be able to:
a. Explain mechanisms of action and risks associated with PARPi alone, as well as in combination with AR inhibitors currently used in practice.
b. Identify and list gene mutations that are predictive biomarkers to identify PARPi + AR inhibitors- responding mCRPC patients.
c. Explain the rationale flow in deciphering when it is finally appropriate to have a mCRPC patient put on a PARPi + AR inhibitor combination treatment.
d. Describe the current landscape of clinical trials that involve the combination of PARPI + AR inhibitor to treat mCRPC.